Literature DB >> 17068976

Regulation of immune cell entry into the central nervous system.

Britta Engelhardt1.   

Abstract

The central nervous system (CNS) has long been regarded as an immune privileged organ implying that the immune system avoids the CNS to not disturb its homeostasis, which is critical for proper function of neurons. Meanwhile, it is accepted that immune cells do in fact gain access to the CNS and that immune responses can be mounted within this tissue. However, the unique CNS microenvironment strictly controls these immune reactions starting with tightly controlling immune cell entry into the tissue. The endothelial blood-brain barrier (BBB) and the epithelial blood-cerebrospinal fluid (CSF) barrier, which protect the CNS from the constantly changing milieu within the bloodstream, also strictly control immune cell entry into the CNS. Under physiological conditions, immune cell migration into the CNS is kept at a very low level. In contrast, during a variety of pathological conditions of the CNS such as viral or bacterial infections, or during inflammatory diseases such as multiple sclerosis, immunocompetent cells readily traverse the BBB and likely also the choroid plexus and subsequently enter the CNS parenchyma or CSF spaces. This chapter summarizes our current knowledge of immune cell entry across the blood CNS barriers. A large body of the currently available information on immune cell entry into the CNS has been derived from studying experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Therefore, most of this chapter discussing immune cell entry during CNS pathogenesis refers to observations in the EAE model, allowing for the possibility that other mechanisms of immune cell entry into the CNS might apply under different pathological conditions such as bacterial meningitis or stroke.

Entities:  

Mesh:

Year:  2006        PMID: 17068976     DOI: 10.1007/400_020

Source DB:  PubMed          Journal:  Results Probl Cell Differ        ISSN: 0080-1844


  29 in total

1.  Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats.

Authors:  Robyn Balden; Amutha Selvamani; Farida Sohrabji
Journal:  Endocrinology       Date:  2012-03-09       Impact factor: 4.736

Review 2.  Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.

Authors:  Yukio Takeshita; Richard M Ransohoff
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  NADPH oxidase and lipid raft-associated redox signaling are required for PCB153-induced upregulation of cell adhesion molecules in human brain endothelial cells.

Authors:  Sung Yong Eum; Ibolya Andras; Bernhard Hennig; Michal Toborek
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-24       Impact factor: 4.219

4.  A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease.

Authors:  Aaron P Kithcart; Gina M Cox; Thais Sielecki; Abigail Short; James Pruitt; Tracey Papenfuss; Todd Shawler; Ingrid Gienapp; Abhay R Satoskar; Caroline C Whitacre
Journal:  FASEB J       Date:  2010-07-12       Impact factor: 5.191

5.  Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis.

Authors:  Pooja Jain; Caroline Coisne; Gaby Enzmann; Robert Rottapel; Britta Engelhardt
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

Review 6.  Strategies for delivering therapeutics across the blood-brain barrier.

Authors:  Georg C Terstappen; Axel H Meyer; Robert D Bell; Wandong Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-03-01       Impact factor: 84.694

7.  Role of nitric oxide in the regulation of immune responses during rabies virus infection in mice.

Authors:  B P Madhu; K P Singh; M Saminathan; R Singh; N Shivasharanappa; A K Sharma; Yashpal S Malik; K Dhama; V Manjunatha
Journal:  Virusdisease       Date:  2016-09-01

Review 8.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 9.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

10.  The choroid plexus response to a repeated peripheral inflammatory stimulus.

Authors:  Fernanda Marques; João C Sousa; Giovanni Coppola; Daniel H Geschwind; Nuno Sousa; Joana A Palha; Margarida Correia-Neves
Journal:  BMC Neurosci       Date:  2009-11-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.